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Abstract 
Background:  Hypertensive intracerebral hemorrhage (HICH) is one of the most 
devastating forms of stroke. Currently, no specific therapies for HICH except general 
medical care. However, in China, medicine of promoting blood circulation (PBC) and 
removing blood stasis (RBS) are widely and efficiently used to treat HICH and become 
a potentially effective treatment for the secondary effects of HICH to alleviate brain 
injury, accelerate neuronal recovery, and improve the prognosis. In order to evaluate 
the safety and effect of PBC and RBS herbal drugs, we design a prospective, rand-
omized, open, double-blind controlled clinical trial on the hematoma enlargement in 
HICH patients treating with PBC and RBS herbal medicine within 6 h time window from 
the symptom onset.
Methods/design: A multicenter, three-group, prospective, randomized, double-
blinded and placebo-controlled clinical trial. Patients aged 18 or older with HICH 
confirmed by CT scan within 6 h from the onset are included. 360 patients will be 
randomized to 3 groups (PBC & RBS & Placebo) within 6 h of ictus. Stratified block 
randomization is undertaken using a sequentially numbered and opaque envelope. 
All subjects must take medicine within 6 h of ictus and have another CT scan at about 
24 h to confirm hematoma expansion. A postal questionnaire to the patients to evalu-
ate their recorvery at 3 months. Primary outcome is the percent change in the volume 
of hematoma at 24 h. Secondary outcomes include: mortality, disability, serious adverse 
events, etc.
Conclusions: The CRRICH Trial is expected to confirm the safety and effect of acute 
intracerebral hemorrhage treated within 6 h of ictus with “RBS” therapy and to deter-
mine whether the traditional therapy can cause hematoma growth after intracerebral 
hemorrhage.
Discussions: This is the first  prospective, multicenter, randomized, placebo-controlled 
clinical trial to investigate herbal medicine whether can induce the incidence of hema-
toma enlargement of AICH patient within the 6 h time window from onset. We need 
the data to keep the herbal clinical usage safety. 
Trial registration clinicaltrials.gov: NCT01918722
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Background
HICH is one of the most devastating forms of stroke which is a main cause of death and 
disability around the world (Roach et al. 2005), playing a  significant part  in morbidity 
and mortality worldwide (Qureshi et al. 2009). The proportion of patients with ICH who 
died within 30  days has risen to nearly 40  %, and most of the survivors cannot make 
a  full  recovery (Qureshi et al. 2009; van Asch et al. 2010). Approximately two-third of 
ICH patients suffer hematoma enlargement within 24 h of ictus (Lim et al. 2008). More-
over, hematoma growth is an independent prognostic determinant (Davis et al. 2006). 
Several reasons may be related to the hematoma enlargement in the early stage of ICH, 
including high blood pressure, “spot” sign of CT scan, sex, age, time window, antico-
agulation drugs (Lim et  al. 2008). But so far there have not been specific therapies or 
treatments preventing hematoma expansion and improve the outcome after ICH. Fur-
thermore, it has been confirmed that neither mini-traumatic operation nor the present 
accessible medicine is proved to be the ideal treatment based on the available evidence-
based medical researches (Morgenstern et al. 2010; Mendelow et al. 2013; Mayer et al. 
2008).
Faced with the limitations of the current available therapies, herbal medicine of pro-
moting blood circulation (PBC) and removing blood stasis (RBS) are widely and effi-
ciently used in Chinese hospitals to treat HICH based on the TCM theory of ‘the blood 
flow outside the vessels is the blood stasis’. However, whether these herbal medicine can 
cause hematoma enlargement leading to serious adverse events is undefined until now 
(Li et al. 2015).
In order to evaluate the safety of PBC and RBS herbal drugs, we design a prospective, 
randomized, open, double-blind controlled clinical trial on the hematoma enlargement 
in HICH patients treating with PBC and RBS herbal medicine within 6 h time window 
from the symptom onset.
Study design and methods
Objective
 The aim of this study is to evaluate the safety and effect of acute intracerebral hem-
orrhage (AICH) treated with “RBS” therapy and to determine whether the traditional 
therapy can cause hematoma growth after intracerebral hemorrhage.
Centre eligibility
There are 13 centers included from all over China. Only hospitals that have been expe-
rienced in clinical trial and previously abided by trial guidelines well are qualified to be 
research centers.
Design
A multicenter, three-group, prospective, randomized, double-blinded and placebo-con-
trolled clinical trial. The study patient flow diagram is displayed in Fig. 1.
Keywords: Intracerebral hemorrhage, Clinical trial, Traditional Chinese medicine, 
Promoting blood circulation, Removing blood stasis
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Fig. 1 Study design diagram. CT computed tomography, CTA computed tomography angiography, NIHSS 
National Institutes of Health Stroke Scale, mRS modified Rankin Scale, BI Barthel Index, GCS Glasgow Coma 
Scale
Page 4 of 11Zeng et al. SpringerPlus  (2016) 5:1466 
Patient population
Entry criteria will be structured to enroll patients aged 18 or older with ICH confirmed 
by CT scan within 6 h after the onset. The exclusion criteria are surgical evacuation of 
hematoma planned within 24 h after the onset and secondary intracerebral hemorrhage. 
More detailed description of the study inclusion and exclusion criteria can be gotten in 
Table 1.
Randomization
We define the herbal medicine as PBC or RBS under the criteria of Chinese Pharmaco-
poeia of 2010 version. The combined herbal drugs, such as relieving heat and calming 
liver Yang, decreasing wind and dispersing phlegm, loosing the bowels, are also under the 
criteria of Chinese Pharmacopoeia of 2010 version. Within 6 h from the onset, partici-
pants will be assigned at random to one of three treatment groups with a ratio of 1:1:1: 
(1) Group A: RBS, stasis-breaking herbal medicine (8 herbals); (2) Group B: PBC, herbal 
medicine without stasis-breaking herbal medicine (6 herbals) and (3) Group C: placebo 
comparator, only placebo. Randomization is generated and stratified in blocks of six by 
PROC PLAN process using the SAS software version 9.13. Stratified block randomiza-
tion  is concealed using a sequentially  numbered and opaque envelope. The number of 
each group will be in balance within research centers and by the baseline NIHSS sever-
ity (≤17 vs. >17), age (>18 years) and hemorrhagic location (basal ganglia vs. all other), 
patients’ sex, baseline Glasgow Coma Scale, duration from onset to the first CT scan.
Intervention
Treatment
The interventions in each group are listed in the Table  2. Treatment is administered 
within 6  h after the onset. The experimental drugs are given as powder prepared by 
Kangyuan Pharamaceutical factory according to a Good Manufacture Practice (GMP). 
Each unit of TCM medicine or placebo is dissolved  into  solution in a cup  of  boiling 
Table 1 Study inclusion and exclusion criteria
At screening, this criteria start. CT computed tomography, GCS Glasgow Coma Scale, TCM Traditional Chinese Medicine, AICH 
acute intracerebral hemorrhage
Inclusion criteria
Ages eligible for study: 18 years or older
Genders eligible for study: both
AICH confirmed by craniocerebral CT scan
Within 6 h after the onset of symptom
GCS ≥ 6
Sign the informed consent form
Exclusion criteria
Secondary intracerebral hemorrhage resulting from trauma, brain tumor, blood diseases, arteriovenous malfor-
mation or aneurysm, etc.
Patients with severe heart, liver or kidney disease
Intolerance to herbal medicine
Patients with allergies
Patients planning a surgical evacuation of hematoma with severe cerebral hernia at super-early stage
Patients with poor compliance
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water of 200 ml. Each patient orally takes 200 ml two times daily for 10 days. And the 
placebo medicine is provided according to the same standardized method. Quality con-
trol is enforced strictly throughout the trial.
CT scanning
At screening, the baseline CT scans are obtained immediately after arriving at treating 
hospital to identify intracerebral hemorrhage; the first follow-up CT scans are done at 
24  h after the onset of symptoms (range 21–27) to assess hematoma growth; and the 
second follow-up CT scans are performed on 10 days (range 8–14) after drug admin-
istration. The hematoma volume is measured by ABC/2 Coniglobus formula (Kothari 
et al. 1996). Hematoma growth is operationally defined as an increase in the hematoma 
volume of >33 % as measured by image analysis on the 24 h CT in comparison with the 
baseline CT scan (Kothari et  al. 1996) (if the first follow-up CT scan cannot be done 
within 24 h from the onset, a 48-h CT scan will be analyzed). Blinding for the two neuro-
radiologists is maintained through analyzation of digital CT data. Computerized plani-
metric techniques are used to calculate the hematoma volume to valuated the primary 
end point. In  a  previous  study, the interobserver  agreement  of this method has been 
proven perfect (Xu et al. 2015).
Follow‑up and outcome evaluation
Clinical assessments are performed at enrollment; at 24 h after the onset of symptoms; 
on the 10th day after admission; and on the 90th day after the stroke. During the  fol-
low-up period, the following scales will used:the GCS assessing the level of conscious-
ness according to the score ranging from 15 (normal) to 3 (deep coma);the NIHSS 
measuring neurologic deficit according to the score ranging from 0 (normal) to 42 
(coma with quadriplegia), the mRS evaluating functional independence, the BI assess-
ing the ability of daily life. More detailed information about the schedule of study visits 
is shown in Table 3.
Adverse event validation
All adverse events will be recorded during  the stay  in hospital and all serious adverse 
events will be recorded 90 days after onset. Clinical events committee, which are com-
posed  of four expert physicians independent of the research centers, will validate all 
adverse events. Relatedness categories are as follows: (1) primary disease-related: events 
obviously due to primary disease with no time relationship to the therapy, or medication. 
Table 2 Groups and interventions
RBS removing blood stasis, PBC promoting blood circulation
Groups Interventions Signa
RBS 8 herbals [with 2 herbals of RBS (Hirudo and 
Tabanus), as well as herbals of PBC and 
other combined herbals]
One dose, bid, by oral or nasogastric tube 
for 10 days
PBC 6 herbals (remove 2 herbals of RBS, left with 
PBC and other combined herbals)
One dose, bid, by oral or nasogastric tube 
for 10 days
Placebo comparator Placebo herbal medicine (with dextrin, farina 
and so on)
One dose, bid, by oral or nasogastric tube 
for 10 days
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(2) concomitant disease-related: events due to diseases instead of the primary disease 
with no time relationship to therapy or medication; (3) TCM medicine-related: events 
obviously due to TCM medicine with no time relationship to other therapy;(4) medicine 
unknown: medicine related but unable to attribute a specific medicine; (5) individual 
difference-related: events have strong time relationship to individual constitution, whose 
allergic constitution are intolerant to traditional Chinese medicine (TCM); (6) other; 
and (7) unknown.
Primary outcome
The primary end-point measure is the percent change in the hematoma volume meas-
ured by ABC/2 Coniglobus formula (Kothari et al. 1996) at the 24th hour after the onset. 
Hematoma growth is operationally defined as an increase in the hematoma volume of 
>33 % as measured by image analysis on the 24 h CT compared with the baseline CT 
scan.
Secondary outcomes
Three secondary clinical efficacy outcomes are included as follows: (1) death owing to 
any cause on the 14th day; (2) disability as defined by mRS score ≤2 on the 90th day; and 
(3) change in NIHSS score at the 24th hour after the onset of symptoms.
In the study two technical efficacy outcomes are included as follows: (1) volume of 
hematoma growth as measured by a CT scan at 24 ± 3 h after onset of symptoms com-
pared with the baseline CT scan; (2) recurrent bleeding measured by CT scan on 10 days 
after drug administration.
Two study safety outcomes are included as follows: (1) all serious adverse events; (2)
hematoma growth at 24 ± 3 h.
Table 3 Study visits
CT computed tomography, CTA computed tomography angiography, NIHSS National Institutes of Health Stroke Scale, mRS 
modified Rankin Scale, BI Barthel Index, GCS Glasgow Coma Scale
Assessment method Screening Onset (0 h) 24 h 10–14 days 90‑day follow‑up
Patient population W – – – –
History W – – – –
Physical examination W W – – –
CT/CTA W W W –
Confirmation of entry criteria W – – – –
Signing consent form W – – – –
Serum and urine test W – – – –
Concomitant medication or treatment W W W W W
GCS W W W W –
NIHSS W W W W W
BI W – W W
mRS – – – W W
Adverse events w w w w W
Summary of patient – – – – W
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Blinding
Before  the  code is broken following receipt of e-mail  notification  of  the  comple-
tion  of  the study, the persons  involved in the research including the investigators, 
subjects and the data  analysts  are blinded to the interventions and outcomes. Only 
the data administrators are permitted access to unblinded data.
Statistical considerations
Sample size
The primary efficacy outcome is the percent change in the volume of hematoma at the 
24th hour after onset in the two treatment groups as compared with the placebo group, 
assessed via the blinded measurement of hematoma by ABC/2 Coniglobus formula. 
The statistical hypothesis on the percentage of hematoma expansion is that the relative 
hematoma volume in subjects of three groups are the same to each other. Power and 
sample size are determined using relative hematoma volume at 24 h as the main out-
come variable. According to the previous literature (Huang et al. 2010; Wang et al. 2013; 
He et  al. 2002), the true proportions of subjects in 3 groups with different rations of 
hematoma expansion at 24 h are presented in Table 4. In this case, the γ is 12.65, pi_max 
38 % and pi_min 7 %. With a two-sided alpha level at 0.05, 285 participants finishing the 
final follow up provide 90 % power to test the hypothesis of the study’s primary effective-
ness, which is calculated by the following formula; assuming that the non-investigation 
rate of the primary outcomes is 20 %, 360 participants will be needed.
Statistical analyses
All analysis  are by  intention  to treat with a beta level of 0.10 and an alpha level of 
0.025 (Type I and Type II error). The primary outcome is the percent change in the 
volume of the hematoma measured by a CT scan at 24 ± 3 h after the onset compared 
with the baseline CT scan. The volumes of the hematoma measured by a CT scan 
will be analyzed using generalized linear mixed models. The subjects and the read-
ers (two neuroradiologists) will be defined as random effects, and the baseline volume 
of hematoma, the time from the onset to CT scanning, and the time from CT scan-
ning to study intervention will be defined as fixed-effect covariates. The percentages 
of changes in the volume of hematoma are transformed to normality and eliminate 
negative values via logarithmic  transformations. Comparisons will be made between 
the two treatment groups with placebo using Bonferroni’s method with a threshold 
of significance of 0.0167. The threshold of significance for all other comparisons was 
0.05. Subjects died before finishing the follow up will be assigned the worst possible 
scores for measures of neurologic deficit and function prognosis. Regarding surviving 
subjects with missing outcome data, the last visit will be carried down. The scores on 
n = 1641.6γ/((sin∧(−1)√(pi_max))− sin∧(−1)√pi_min∧2
Table 4 Hypothesized true outcomes for sample size calculations
RBS removing blood stasis, PBC promoting blood circulation
Randomized group PBC RBS Placebo
Percentage of change 7 16 38
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mRS will be analyzed in a cumulative logit model, with statistical adjustment for age, 
the baseline hematoma volume, the site of hemorrhage, and the baseline neurologi-
cal status. The scores on the BI and NIHSS will be analyzed with Wilcoxon rank-sum 
tests. The difference of the frequency of SAE in the three groups at 3 months will be 
analyzed with Fisher’s exact test or the Chi square test. All dates will be analyzed via 
SPSS software, version 21.0.
Lost‑to‑follow‑up and missing data
It is supposed that there is no missing safety data on SAE, because of the  care-
ful  observation and detailed  records while in hospital. For surviving patients with 
missing outcome data, the last observation was carried forward. Regarding other incom-
plete primary outcome data, we will use multiple imputation to  fill in  missing  data 
with standard statistical procedure.
Data and safety monitoring
The Data Safty Monitoring Committee deliberates the data from intermediate safety 
analysis report and contacts the Trial Steering Committee. Interim results are extremely 
secret and once one of the three groups shows a distinct advantage over others, the com-
mittee will counsel to end the study ahead of schedule.
Rationale for the design
Justification for the choice of three groups
In the study, we design three groups to verify the better efficacy of combining RBS with 
PBC herbal medicine based on formula components analysis/methods. As recorded 
in the Chinese Pharmacopoeia of 2010 version (Chinese Pharmacopoeia Commission 
2010), RBS herbal medicine should be combined with PBC and other herbals correctly 
in the Traditional Chinese Medicine Formula in order to avoid the rebleeding risk. Some 
herbal have strong RBS and promoting blood circulation function, for example, leech 
can cause rebleeding (Liu et al. 2012). Some others have two-way adjustment pharma-
cological effect, for example, Radix notoginseng can not only promote blood circulation 
but also stop bleeding. Traditionally, the prescription of Chinese medicine to learn is 
through reasonable compatibility other than a single drug, to eliminate this rebleeding 
risk.
Justification for the choice of the therapeutic time window
The decision on the time of beginning PBS therapy within 6 h after the onset of symp-
toms is  made  on  the  basis  of the data from previous studies (Xu et  al. 2015). Among 
most (83  %) of patients with hematoma growth done the first-time CT scan within 
6 h after the onset, enlargement after 24 h of onset happens rarely (Kazui et al. 1996). 
So some neurologists show their opinion that PBC and RBS herbal medicine should 
be used after 24 h of onset in order to prevent rebleeding risk (Wanzhng et al. 2004). 
However others support that PBC and RBS herbal medicine should be administrated 
as sooner as possible (Li 2003). And furthermore, Guo et al.’s (2005) previous study did 
not show deterioration of condition of the AICH patients who were treated with herbal 
compound within 6 h time window from the onset, suggesting better curative effect for 
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earlier therapy. This finding might reduce hospital stay, healthcare-related expenses, as 
well as complications and mortality.
Discussion
Further prospective, multicenter, randomized, placebo control clinical trials are needed 
to provide better quality evidence, though in a retrospective study (Xu et al. 2015), we 
found that PBC and RBS herbal medicine were not associated with an increased risk of 
hematoma growth within 24 h after the onset of symptoms. Meanwhile, a meta-analysis 
(Li et al. 2015) which included 9 randomized-controlled clinical trials with 798 individu-
als showed that PBC and RBS single therapy and combination  therapy for acute ICH 
could reduce the  volumes of  brain  hematoma  and  cerebral  edema, improve the neu-
ral function and reduce the mortality and disability rate. Moreover, unlike western con-
ventional medication group, fewer adverse reactions occurred in herb medicine group. 
In spite of the obviously positive results, It’s too early to draw conclusion about the effi-
cacy and safety of PBC & RBS for ICH since the limitation of the included studies in the 
meta-analysis. Therefore, high-quality RCTs are needed.
The CRRICH Trial will provide definitive information on the efficacy and safety of 
the RBS therapy. The trial is designed to learn lessons from study of earlier conserva-
tive therapies that cannot demonstrate the treatment benefit of TCM with RBS rather 
well. Unlike those prior studies (Fan and Jin 2000), the trial set three groups (PBS & RPS 
& Placebo), better observating the efficacy of RBS or PBS to confirm whether PBC and 
RBS herbal medicine induce the incidence of hematoma enlargement of AICH patients 
within the 6 h time window from onset. The shortages of prior studies are as follows: 
(1) most studies are retrospective, unblinded trials; (2) mixed PBS with RBS; (3) time 
window from onset is 24 h or later; (4) not multicenter RCT. In order to make up for 
these limitations, we have designed a prospective, 13 hospitals, randomized, placebo-
controlled clinical trial (clinicaltrials.gov: NCT01918722) to confirm if PBC and RBS 
herbal medicine induce the incidence of hematoma enlargement of AICH patient within 
the 6 h time window from onset. The trial enrolled its first patient on October 25, 2013. 
And 280 cases have recruited so far. The study is still ongoing until all 360 patients are 
completed in December 2016. When completed, we will provide pivotal data allowing.
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